Company intelligence / Profile preview

Averitas Pharma, Inc.

Ownership: Private
Employees: ~181
Development stage: Commercial

Overview

Averitas Pharma commercializes QUTENZA (capsaicin) 8% topical system, a non-opioid, non-systemic pain treatment approved in the US for neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy of the feet. The company is currently conducting Phase III trials for post-surgical neuropathic pain with topline results expected in Q4 2025.

Therapeutic areas: Neurology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

capsaicin

Commercial

Indications: Postherpetic neuralgia, Diabetic peripheral neuropathy

Beyond the preview

Go deeper on Averitas Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Averitas Pharma, Inc..

Explore the full profile